BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26395117)

  • 21. Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers.
    Bernadach M; Lapeyre M; Dillies AF; Miroir J; Casile M; Moreau J; Molnar I; Ginzac A; Pham-Dang N; Saroul N; Durando X; Biau J
    BMC Cancer; 2021 Apr; 21(1):360. PubMed ID: 33827483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.
    Céruse P; Cosmidis A; Belot A; Rabilloud M; Fuchsmann C; Poupart M; Ramade A; Tartas S; Favrel V; Pommier P; Zrounba P; Fayette J
    Anticancer Drugs; 2014 Sep; 25(8):970-5. PubMed ID: 24849707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.
    Lefebvre JL; Pointreau Y; Rolland F; Alfonsi M; Baudoux A; Sire C; de Raucourt D; Malard O; Degardin M; Tuchais C; Blot E; Rives M; Reyt E; Tourani JM; Geoffrois L; Peyrade F; Guichard F; Chevalier D; Babin E; Lang P; Janot F; Calais G; Garaud P; Bardet E
    J Clin Oncol; 2013 Mar; 31(7):853-9. PubMed ID: 23341517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic strategies, oncologic and swallowing outcomes and their predictive factors in patients with locally advanced hypopharyngeal cancer.
    Mattei P; Thamphya B; Chamorey E; Scheller B; Château Y; Dassonville O; Poissonnet G; Culié D; Koulmann PH; Hechema R; Sudaka A; Saada E; Benezery K; Demard F; Elaldi R; Bozec A
    Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3629-3637. PubMed ID: 35076745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer.
    Zelefsky MJ; Kraus DH; Pfister DG; Raben A; Shah JP; Strong EW; Spiro RH; Bosl GJ; Harrison LB
    Head Neck; 1996; 18(5):405-11. PubMed ID: 8864731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer.
    Pfister DG; Strong E; Harrison L; Haines IE; Pfister DA; Sessions R; Spiro R; Shah J; Gerold F; McLure T
    J Clin Oncol; 1991 May; 9(5):850-9. PubMed ID: 2016629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and
    Wichmann G; Krüger A; Boehm A; Kolb M; Hofer M; Fischer M; Müller S; Purz S; Stumpp P; Sabri O; Dietz A; Kluge R
    Eur J Cancer; 2017 Feb; 72():144-155. PubMed ID: 28033526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term update of the 24954 EORTC phase III trial on larynx preservation.
    Henriques De Figueiredo B; Fortpied C; Menis J; Lefebvre JL; Barzan L; de Raucourt D; Geoffrois L; Giurgea L; Hupperets P; Leemans CR; Licitra L; Rolland F; Tesselaar M; Vermorken JB; Grégoire V;
    Eur J Cancer; 2016 Sep; 65():109-12. PubMed ID: 27494036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma.
    Joshi P; Patil V; Joshi A; Norohna V; Chaturvedi P; Chaukar D; Pai P; Nair D; Juvekar S; Agarwal JP; D'Cruz AK; Prabhash K
    Indian J Cancer; 2013; 50(1):25-30. PubMed ID: 23713041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
    Tai SK; Yang MH; Wang LW; Tsai TL; Chu PY; Wang YF; Huang JL; Chang SY
    Jpn J Clin Oncol; 2008 Aug; 38(8):521-7. PubMed ID: 18697758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy.
    Lim SH; Lee SJ; Ahn MJ; Park K; Sun JM
    Jpn J Clin Oncol; 2016 Jan; 46(1):40-5. PubMed ID: 26561556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent chemoradiotherapy improves survival in patients with hypopharyngeal cancer.
    Paximadis P; Yoo G; Lin HS; Jacobs J; Sukari A; Dyson G; Christensen M; Kim H
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1515-21. PubMed ID: 21658855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
    Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
    Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.
    Spector JG; Sessions DG; Haughey BH; Chao KS; Simpson J; El Mofty S; Perez CA
    Laryngoscope; 2001 Jun; 111(6):1079-87. PubMed ID: 11404625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma.
    Yoon MS; Chung WK; Ahn SJ; Nam TK; Nah BS; Song JY; Lim SC; Lee JK
    Acta Otolaryngol; 2008 May; 128(5):590-6. PubMed ID: 18421617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoselection combined with alternating chemoradiotherapy or surgery for hypopharyngeal cancer.
    Matsuzuka T; Sato H; Suzuki R; Suzuki M; Saijoh S; Ikeda M; Nakaegawa Y; Tani A; Imaizumi M; Matsui T; Nomoto Y; Nomoto M; Tada Y; Suzuki Y; Omori K
    Laryngoscope; 2016 Jun; 126(6):1349-53. PubMed ID: 26536058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma.
    Li R; Ye L; Zhu Y; Ding H; Wang S; Ying H; Wu C; Zhou L; Wang X; Tian S
    Head Neck; 2022 Sep; 44(9):2018-2029. PubMed ID: 35915867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGR1 regulates radiation-induced apoptosis in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2015 Apr; 33(4):1717-22. PubMed ID: 25710185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncological results of surgical treatment versus organ-function preservation in larynx and hypopharynx câncer.
    Calvas OIJ; Ramos DM; Matos LL; Kulcsar MAV; Dedivitis RA; Brandão LG; Cernea CR
    Rev Assoc Med Bras (1992); 2017 Dec; 63(12):1082-1089. PubMed ID: 29489975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel-Cisplatin-Fluorouracil Induction Chemotherapy for Larynx Preservation in Patients with Locally Advanced Hypopharyngeal Cancer: Predictive Factors of Oncologic and Functional Outcomes.
    Mattei P; Gal J; Chamorey E; Dassonville O; Poissonnet G; Aloi D; Barret M; Safta I; Saada E; Sudaka A; Culié D; Bozec A
    J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.